Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)
Calluna Pharma AS (Calluna), a clinical-stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that it has completed enrollment in its global Phase 2 AURORA study of CAL101 for IPF.
Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis
Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the first patients have been dosed in the Phase 2 AURORA study of CAL101 for IPF.
Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference
Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that the company will present three posters related to both of its pipeline programs at the American Thoracic Society (ATS) 2025 International Conference (ATS 2025). ATS 2025 is being held May 16 – 21, 2025 at the Moscone Center in San Francisco.
